MindRank secures $52 million Series B to scale its AI-driven drug discovery platform and advance its oral GLP-1 candidate MDR-001.
This briefing summarizes an external report from BioXconomy. Open the full story for complete coverage and charts.

BioXconomy · Jul 13, 2026 · 2 Min Read
MindRank secures $52 million Series B to scale its AI-driven drug discovery platform and advance its oral GLP-1 candidate MDR-001.
This briefing summarizes an external report from BioXconomy. Open the full story for complete coverage and charts.